- Home
- ADAP vs ADAG Comparison
ADAP vs ADAG Comparison
Compare ADAP & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- ADAG
- Stock Information
- Founded
- ADAP 2008
- ADAG 2011
- Country
- ADAP United Kingdom
- ADAG China
- Employees
- ADAP 506
- ADAG N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- ADAP Health Care
- ADAG Health Care
- Exchange
- ADAP Nasdaq
- ADAG Nasdaq
- Market Cap
- ADAP 75.5M
- ADAG 81.9M
- IPO Year
- ADAP 2015
- ADAG 2021
- Fundamental
- Price
- ADAP $0.29
- ADAG $1.61
- Analyst Decision
- ADAP Strong Buy
- ADAG Strong Buy
- Analyst Count
- ADAP 5
- ADAG 1
- Target Price
- ADAP $1.83
- ADAG $8.00
- AVG Volume (30 Days)
- ADAP 777.8K
- ADAG 13.0K
- Earning Date
- ADAP 05-13-2025
- ADAG 03-24-2025
- Dividend Yield
- ADAP N/A
- ADAG N/A
- EPS Growth
- ADAP N/A
- ADAG N/A
- EPS
- ADAP N/A
- ADAG N/A
- Revenue
- ADAP $178,032,000.00
- ADAG $103,204.00
- Revenue This Year
- ADAP N/A
- ADAG $6,488.89
- Revenue Next Year
- ADAP $69.81
- ADAG $57.50
- P/E Ratio
- ADAP N/A
- ADAG N/A
- Revenue Growth
- ADAP 195.34
- ADAG N/A
- 52 Week Low
- ADAP $0.20
- ADAG $1.33
- 52 Week High
- ADAP $1.48
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- ADAP 51.38
- ADAG 52.98
- Support Level
- ADAP $0.30
- ADAG $1.51
- Resistance Level
- ADAP $0.32
- ADAG $1.74
- Average True Range (ATR)
- ADAP 0.02
- ADAG 0.10
- MACD
- ADAP 0.01
- ADAG 0.03
- Stochastic Oscillator
- ADAP 67.44
- ADAG 65.79
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
About ADAG Adagene Inc.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.